CTSO
Cytosorbents Corporation
CTSO lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CTSO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
CTSO's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CTSO PE Valuation
CTSO has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CTSO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
CTSO has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CTSO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$5.80 | -$2.40 |
| Q1 2026 | -$3.80 | +$1.80 |
| Q4 2025 | -$2.60 | +$5.00 |
| Q3 2025 | -$3.60 | +$3.60 |
| Q2 2025 | -$3.40 | +$7.20 |
| Q1 2025 | -$5.60 | +$6.20 |
| Q4 2024 | -$7.60 | +$5.20 |
| Q3 2024 | -$7.20 | +$3.60 |
CTSO has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CTSO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $9.6M | +0.2% |
| Q1 2026 | $8.9M | +1.6% |
| Q4 2025 | $9.2M | +42% |
| Q3 2025 | $9.5M | +1% |
| Q2 2025 | $9.6M | -2.8% |
| Q1 2025 | $8.7M | -11% |
| Q4 2024 | $6.5M | -25% |
| Q3 2024 | $9.4M | +6.6% |
CTSO's revenue has grown year over year for four quarters in a row: $10M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -27% | +10 points |
| Q1 2026 | -34% | +10 points |
| Q4 2025 | -47% | +15 points |
| Q3 2025 | -30% | +17 points |
| Q2 2025 | -38% | -3 points |
| Q1 2025 | -45% | +5.8 points |
| Q4 2024 | -62% | +47 points |
| Q3 2024 | -47% | +37 points |
CTSO's operating margin was −27% last quarter, up 10 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CTSO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CTSO on profitability, with a higher operating margin.
CTSO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$597K | +$949.9K |
| Q1 2026 | -$1.2M | +$2.3M |
| Q3 2025 | -$2.6M | -$132.8K |
| Q2 2025 | -$1.5M | +$3.2M |
| Q1 2025 | -$3.5M | +$1.4M |
| Q3 2024 | -$2.5M | +$2.9M |
| Q2 2024 | -$4.8M | +$1.9M |
| Q1 2024 | -$4.9M | -$1.3M |
CTSO has burned cash in almost every quarter: −$9M over the past year, against −$12M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CTSO on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTSO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +3.4K shares |
| 1 year | -6.5% | -218K shares |
| 3 years | +43% | +940K shares |
| 5 years | +45% | +974K shares |
| Available history | +94% | +1.5M shares |
CTSO has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CTSO Net Leverage
CTSO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CTSO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.9 | Neutral |
| Stochastic | 31.3 | Neutral |
CTSO's weekly RSI is 40 (neutral) and its Stochastic is 31 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CTSO PE vs Healthcare Sector
CTSO has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CTSO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.54 | 18% above |
| 20 week MA | $6.09 | 12% below |
| 50 week MA | $9.78 | 45% below |
| 100 week MA | $14.6 | 63% below |
| 200 week MA | $25.4 | 79% below |
CTSO has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CTSO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $76.6 | $166.2 | +117% |
| 2021 | $166.2 | $89.0 | -46% |
| 2022 | $89.0 | $28.0 | -69% |
| 2023 | $28.0 | $22.2 | -21% |
| 2024 | $22.2 | $18.8 | -15% |
| 2025 | $18.8 | $13.6 | -28% |
| 2026 YTD | $13.6 | $5.37 | -61% |
CTSO has finished five years in a row lower, and it's down 61% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over CTSO on returns for 2026, with the stronger performance.